Philip Marder

1.1k total citations
45 papers, 929 citations indexed

About

Philip Marder is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Philip Marder has authored 45 papers receiving a total of 929 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 16 papers in Immunology and 10 papers in Oncology. Recurrent topics in Philip Marder's work include Monoclonal and Polyclonal Antibodies Research (9 papers), Immune Response and Inflammation (9 papers) and Asthma and respiratory diseases (9 papers). Philip Marder is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (9 papers), Immune Response and Inflammation (9 papers) and Asthma and respiratory diseases (9 papers). Philip Marder collaborates with scholars based in United States, Netherlands and Singapore. Philip Marder's co-authors include Lisa J. Green, Stephen M. Spaethe, Christopher A. Slapak, Jon R. Schmidtke, Larry L. Froelich, Richard M. Schultz, Eric R. Prossnitz, Alexis Traynor‐Kaplan, L D Apelgren and Raymond F. Brown and has published in prestigious journals such as The Journal of Immunology, Clinical Cancer Research and Biochemical and Biophysical Research Communications.

In The Last Decade

Philip Marder

45 papers receiving 889 citations

Peers

Countries citing papers authored by Philip Marder

Since Specialization

Citations

This map shows the geographic impact of Philip Marder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Marder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Marder more than expected).

Fields of papers citing papers by Philip Marder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Marder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Marder. The network helps show where Philip Marder may publish in the future.

Co-authorship network of co-authors of Philip Marder

This figure shows the co-authorship network connecting the top 25 collaborators of Philip Marder. A scholar is included among the top collaborators of Philip Marder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip Marder. Philip Marder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Flow cytometry in drug discovery and development	Wiley eBooks	Virginia Litwin, Philip Marder	4
2	Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells11Abbreviations: MDR, multidrug resistance (resistant); Pgp,P-glycoprotein; Rh123, rhodamine 123; DNR, daunorubicin; TMBY,trimethoxybenzoylyohimbine; CsA, cyclosporin A; VER, verapamilhydrochloride; and MFI, mean fluorescence intensity.	Biochemical Pharmacology	Lisa J. Green, Philip Marder et al.	57
3	In vivo regulation of apoptosis in metaphyseal trabecular bone of young rats by synthetic human parathyroid hormone (1-34) fragment	Bone	Dinesh Stanislaus, Xiaonan Yang et al.	55
4	The Discovery of LY293111, a Novel, Potent and Orally Active Leukotriene B4 Receptor Antagonist of the Biphenylphenol Class	Advances in experimental medicine and biology	Michael J. Sofia, Paul E. Floreancig et al.	7
5	Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis	Cancer Chemotherapy and Pharmacology	John L. Tonkinson, Philip Marder et al.	72
6	The regulation of CD11b integrin levels on human blood leukocytes and leukotriene B4-stimulated skin by a specific leukotriene B4 receptor antagonist (LY293111)	Biochemical Pharmacology	E.M.G.J. de Jong, P.E.J. van Erp et al.	20
7	The effects of LY293111Na, a leukotriene B4 receptor antagonist, on the pulmonary neutrophilia and CD11b expression caused by inhalation of a leukotriene B4 aerosol in rhesus monkeys.	Journal of Pharmacology and Experimental Therapeutics	David L. Allen, Wherly P. Hoffman et al.	11
8	Inhibition of ex vivo neutrophil activation by oral LY293111, a novel leukotriene B4 receptor antagonist	British Journal of Clinical Pharmacology	Philip Marder, Stephen M. Spaethe et al.	16
9	Blockade of human neutrophil activation by 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]phenoxy]benzoic acid (LY293111), a novel leukotriene B4 receptor antagonist	Biochemical Pharmacology	Philip Marder, J. Scott Sawyer et al.	43
10	Investigation of neutrophil signal transduction using a specific inhibitor of phosphatidylinositol 3-kinase.	The Journal of Immunology	Chris J. Vlahos, William F. Matter et al.	162
11	Total synthesis and biological properties of novel antineoplastic (chloromethyl)furanoindolines: an asymmetric hydroboration mediated synthesis of the alkylation subunits	Journal of Medicinal Chemistry	F. MOHAMADI, Philip Marder et al.	40
12	o-Phenylphenols: potent and orally active leukotriene B4 receptor antagonists	Journal of Medicinal Chemistry	Michael J. Sofia, Paul E. Floreancig et al.	8
13	Ligand Interactions with the RGD Recognition Site Alter Binding of GPIIb-IIIa Reactive Monoclonal Antibody to Human Platelets	Biochemical and Biophysical Research Communications	Philip Marder	2
14	Flow cytometric evaluation of the effects of leukotriene B4 receptor antagonists (LY255283 and SC-41930) on calcium mobilization and integrin expression of activated human neutrophils	Prostaglandins Leukotrienes and Essential Fatty Acids	Philip Marder, Richard M. Schultz et al.	16
15	Effects of two leukotriene B4 (LTB4) receptor antagonists (LY255283 and SC-41930) on LTB4-induced human neutrophil adhesion and superoxide production	Prostaglandins Leukotrienes and Essential Fatty Acids	Richard M. Schultz, Philip Marder et al.	10
16	Selective cloning of hybridoma cells for enhanced immunoglobulin production using flow cytometric cell sorting and automated laser nephelometry	Cytometry	Philip Marder, Rebecca L. Fouts et al.	29
17	Characterization of the Human Tumor and Normal Tissue Reactivity of the KS1/4 Monoclonal Antibody	Hybridoma	Thomas F. Bumol, Philip Marder et al.	56
18	Reactivation of class II antigen expression in murine macrophage hybrids.	The Journal of Immunology	Steven H. Zuckerman, Robert D. Schreiber et al.	7
19	Cyclosporin a inhibits helper/inducer surface antigen expression on activated human lymphocytes	International Journal of Immunopharmacology	Philip Marder, Jon R. Schmidtke	8
20	Potentiation of Leu 11+ natural cytotoxicity by human interleukin 2	Clinical Immunology and Immunopathology	Edwin W. Ades, Philip Marder et al.	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact